Irwin C, Fyles A, Wong C S, Cheung C M, Zhu Y
Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Canada.
Radiother Oncol. 1996 Mar;38(3):257-61. doi: 10.1016/0167-8140(95)01702-x.
Sixty patients treated with whole abdominal radiotherapy who had remained disease-free since completion of treatment participated in a study to assess the late clinical and biochemical effects of bilateral renal irradiation. Minimum follow-up was 5 years with a maximum of 20 years and a median of 9 years. Fifty-two patients in the study group were treated for primary ovarian cancer. Seven had non-Hodgkins lymphoma arising in the gastrointestinal tract and one patient had a carcinoid tumour arising in small bowel. None of the patients received chemotherapy. Abdominal radiation was given using an open beam technique to a mean dose of 22.92 Gy (range 6.68-27.54 Gy) in 1.02 to 1.25 Gy fractions treated once daily. Posterior kidney shields were used in order to limit the renal dose to < 20 Gy. Mean radiation dose to both kidneys (retrospectively calculated) was 19.28 Gy (range 6.68-22.99 Gy). Patients ranged in age from 32-81 years with a median of 61 years. No patient had clinical evidence of renal impairment. Nine patients were hypertensive prior to radiotherapy and a further five patients became hypertensive after treatment. Serum creatinine values ranged from 44-123 mumol/l, with a mean of 87 mumol/l. Creatinine clearance ranged from 0.61-2.38 ml/s (mean 1.28 ml/s). Tubular function tests revealed one borderline high 24-h protein excretion and normal 24-h phosphorous and uric acid. Using a multiple linear regression analysis with creatinine clearance as the endpoint, age was the only significant variable (P < 0.00001) and renal dose and interval from treatment were not independently significant. There was no evidence of late renal toxicity more than 5 years after whole abdominal radiotherapy delivered with this technique and dose/fractionation schedule, and using the clinical and biochemical endpoints assessed in this study.
60例接受全腹放疗且自治疗结束后一直无疾病复发的患者参与了一项研究,以评估双侧肾脏放疗的晚期临床和生化效应。最小随访时间为5年,最长为20年,中位随访时间为9年。研究组中的52例患者因原发性卵巢癌接受治疗。7例患有起源于胃肠道的非霍奇金淋巴瘤,1例患者患有起源于小肠的类癌肿瘤。所有患者均未接受化疗。采用开放野技术进行腹部放疗,每天照射1次,每次剂量为1.02至1.25 Gy,平均剂量为22.92 Gy(范围6.68 - 27.54 Gy)。使用后位肾脏防护板以将肾脏剂量限制在<20 Gy。双侧肾脏的平均辐射剂量(回顾性计算)为19.28 Gy(范围6.68 - 22.99 Gy)。患者年龄在32 - 81岁之间,中位年龄为61岁。没有患者有肾功能损害的临床证据。9例患者在放疗前患有高血压,另外5例患者在治疗后出现高血压。血清肌酐值范围为44 - 123 μmol/l,平均为87 μmol/l。肌酐清除率范围为0.61 - 2.38 ml/s(平均1.28 ml/s)。肾小管功能测试显示1例24小时蛋白排泄临界值高,24小时磷和尿酸正常。以肌酐清除率作为终点进行多元线性回归分析,年龄是唯一显著变量(P < 0.00001),肾脏剂量和治疗后的时间间隔并非独立显著。采用该技术和剂量/分割方案进行全腹放疗,并使用本研究中评估的临床和生化终点指标,5年以上无晚期肾脏毒性的证据。